AOTI, Inc.
LLSE:AOTI130.00
GBX
0.00
(0.00%)
ISIN
US03690C1027
CUSIP
03690C102
Return %
Stock
S&P 500
1Y
271.43
14.20
3Y
- -
81.12
5Y
- -
68.34
Capital Structure
USD
•
in mil. unless spec.Working Capital
USD
•
in mil. unless spec.Growth Rates
USD
•
in mil. unless spec.Semi-annual Revenue
USD
•
in mil. unless spec.Semi-annual Earnings Per Share
USD
•
in mil. unless spec.Semi-annual Dividends Per Share
USD
•
in mil. unless spec.Company Description
- CEO
- Michael Stephen Griffiths
- Full Time Employees
- 90
- Sector
- Health technology
- Industry
- Medical specialties
- Address
- 3512 Seagate Way Oceanside CA United States 92056
- IPO Date
- Jun 18, 2024
- Website
- aotinc.net
- Similar Companies
- Business
- AOTI, Inc. (AIM: AOTI) develops, manufactures, rents and sells advanced medical devices focused on the durable healing of chronic and acute wounds, particularly diabetic foot ulcers, venous leg ulcers and other hard-to-heal conditions, for healthcare providers, payers and patients worldwide; its core products include the patented multi-modality Topical Wound Oxygen (TWO2) therapy delivering cyclical high-pressure oxygen, non-contact compression and humidification via the TWO2 Extremity Chamber and TWO2 Multi-Patch systems, and the NEXA Negative Pressure Wound Therapy (NPWT) disposable multi-patient system. Founded in 2006 and headquartered in Oceanside, California, with key operations in Galway, Ireland, the company serves the over $14 billion advanced wound care market across the US (including Veterans Administration, nine Medicaid states, workers' compensation, skilled nursing facilities and long-term care), UK, Europe, Canada, Australia, China and Saudi Arabia, holding over 80% share of the topical oxygen therapy segment and treating more than 30,000 patients to date with FDA, CE Mark, MHRA, Health Canada, TGA and other clearances. Recent developments include a successful initial public offering on AIM in June 2024 raising $19.9 million net proceeds to fuel commercial expansion and debt reduction; a five-year extension of its Veterans Administration Federal Supply Schedule contract on improved terms in December 2024; US FDA 510(k) clearance in 2024 for NEXA NPWT home care use and a distribution agreement with a large US distributor; expansion into three additional Medicaid states bringing the total to nine; award of TWO2 therapy to the NHS Supply Chain Advanced Wound Care 2025 framework in the UK; commencement of a multinational randomized controlled trial for venous leg ulcers; and progression toward Medicare reimbursement coverage for 65 million Americans via Centers for Medicare & Medicaid Services discussions.